Beam Therapeutics price target raised to $37 from $34 at Clear Street

Clear Street raised the firm’s price target on Beam Therapeutics (BEAM) to $37 from $34 and keeps a Buy rating on the shares following the Q3 report. BEAM-103 has dosed the first patient in a healthy volunteer study while the next major catalyst for the shares being the interim update from BEAM-302 in early 2026, the analyst tells investors in a research note. Clear adds that Beam owns 17% of private company Orbital Therapeutics, which amounts to $255M in its recently announced takeout.